Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Cardiovascular Risk and Outcomes in Patients With Cancer: The TRACE-Cancer Study (TRACE-Cancer)

Cardiovascular Risk Stratification, Clinical Outcomes, and Prevention in Patients With Cancer: A Nationwide Multicenter Retrospective and Prospective Cohort Study

The goal of this observational study is to investigate cardiovascular risks and long-term outcomes in adults with cancer in China. The main questions it aims to answer are:What is the risk of major adverse cardiovascular events (MACE) in patients with different types of cancer and anticancer treatments?Can clinical characteristics, cardiovascular assessments, and biomarkers help predict cardiovascular events and identify high-risk patients?This nationwide, multicenter study includes both retrospective and prospective cohorts. Researchers will collect clinical information from medical records and follow participants over time to assess cardiovascular health and outcomes.Participants in the prospective cohort will undergo cardiovascular assessments and follow-up as part of their clinical care. No experimental treatments will be assigned.

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

The TRACE-Cancer Study is a nationwide, multicenter, observational cohort study designed to evaluate cardiovascular risks and long-term outcomes in adults with cancer.The study includes a retrospective cohort of patients diagnosed between January 2018 and June 2026 and a prospective cohort enrolled from June 2026, with follow-up planned through December 2036.Clinical data will include cancer characteristics, anticancer treatments, cardiovascular risk factors, medical history, laboratory tests, cardiac imaging, and biomarkers. The primary outcome is major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke, and serious arrhythmias. Secondary outcomes include all-cause mortality, cancer-specific mortality, other cardiovascular complications, and changes in cardiac function.The study will also develop and validate cardiovascular risk prediction models to support early identification and prevention of cardiovascular complications in patients with cancer. All treatment decisions will follow routine clinical practice without study-assigned interventions.

Tipo di studio

Osservativo

Iscrizione (Stimato)

50000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consists of adults aged 18 years or older with pathologically or cytologically confirmed malignancies receiving cancer-related care at participating medical centers across China. The study includes two cohorts: a retrospective cohort of patients diagnosed and treated between January 2018 and June 2026, and a prospective cohort enrolling eligible patients from June 2026 onward. Participants will be recruited from general hospitals, cancer centers, and cardiovascular centers. All cancer types and stages are eligible, regardless of anticancer treatment or baseline cardiovascular status. Clinical information and long-term cardiovascular outcomes will be collected using standardized procedures. Biospecimen availability is not required for enrollment.

Descrizione

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. Patients with a pathologically or cytologically confirmed diagnosis of malignancy.
  3. Patients receiving cancer-related diagnosis, treatment, clinical assessment, or follow-up at participating centers.
  4. For the retrospective cohort, availability of traceable clinical records, including medical history, pathology reports, treatment information, or follow-up data.
  5. For the prospective cohort, provision of informed consent by the participant or legally authorized representative, in accordance with applicable ethical requirements.
  6. Availability of baseline clinical information and the ability to obtain follow-up information through clinical records, outpatient visits, hospitalization records, telephone contact, or other approved sources.

Exclusion Criteria:

  1. Inability to confirm a diagnosis of malignancy.
  2. For the retrospective cohort, insufficient essential clinical information to establish baseline status or ascertain the primary outcome.
  3. For the prospective cohort, refusal to provide informed consent when required.
  4. Duplicate enrollment of the same participant at the same center; only the first eligible record will be retained.
  5. Other circumstances determined by the investigators to prevent appropriate participation or reliable follow-up.

Additional Consideration:

Patients will not be excluded based on cancer type, cancer stage, anticancer treatment modality, pre-existing cardiovascular conditions, comorbidities, or expected survival. The availability of biological specimens is not required for enrollment, and participants without available biospecimens will remain eligible for the clinical cohort.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Coorti e interventi

Gruppo / Coorte
Retrospective Cohort

Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who received medical care at participating centers between January 2018 and June 2026. Clinical characteristics, anticancer treatments, cardiovascular risk factors, and long-term outcomes will be collected retrospectively from existing medical records and available follow-up data.

Prospective Cohort

Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who are prospectively enrolled at participating centers beginning in June 2026. Clinical characteristics, anticancer treatments, cardiovascular assessments, and outcomes will be collected at baseline and during longitudinal follow-up through December 2036.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to First Major Adverse Cardiovascular Event (MACE)
Lasso di tempo: From baseline to the first qualifying event or the end of follow-up, up to 10 years.

Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal ischemic or hemorrhagic stroke, or serious arrhythmia. Serious arrhythmias include sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. The first qualifying event will be identified through medical records and follow-up information and adjudicated according to standardized diagnostic criteria.

From baseline to the first qualifying event or the end of follow-up, up to 10 years.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to All-Cause Mortality
Lasso di tempo: From baseline to death or the end of follow-up, up to 10 years.

Time from baseline to death from any cause. Death events and dates will be identified using hospital medical records, available death registration information, and follow-up records. The cumulative incidence and time to all-cause mortality will be assessed during follow-up.

From baseline to death or the end of follow-up, up to 10 years.
Time to Cancer-Specific Mortality
Lasso di tempo: From baseline to cancer-related death or the end of follow-up, up to 10 years.

Time from baseline to death attributed to the underlying malignancy or cancer-related complications. Cancer-specific mortality will be determined based on available medical records, documented causes of death, and follow-up information. Deaths from other causes will be treated as competing events in the analysis of cancer-specific mortality.

From baseline to cancer-related death or the end of follow-up, up to 10 years.
Time to Cardiovascular Death
Lasso di tempo: From baseline to cardiovascular death or the end of follow-up, up to 10 years.

Time from baseline to death attributed to cardiovascular causes, including fatal myocardial infarction, heart failure, stroke, sudden cardiac death, or other cardiovascular conditions. Cardiovascular death will be determined using available medical records, documented causes of death, and standardized adjudication criteria. Noncardiovascular deaths will be treated as competing events.

From baseline to cardiovascular death or the end of follow-up, up to 10 years.
Time to First Nonfatal Myocardial Infarction
Lasso di tempo: From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.

Time from baseline to the first nonfatal myocardial infarction during follow-up. Myocardial infarction will be identified from clinical records and hospitalization data and confirmed according to standardized diagnostic criteria, including clinical presentation, cardiac troponin measurements, electrocardiographic findings, and available cardiac imaging or coronary angiographic evidence.

From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
Time to First Hospitalization for Heart Failure
Lasso di tempo: From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.

Time from baseline to the first hospitalization for newly diagnosed or worsening heart failure requiring inpatient treatment. Heart failure events will be identified through hospitalization records and confirmed using clinical symptoms, signs, cardiac imaging findings, laboratory results, and standardized diagnostic criteria.

From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
Time to First Nonfatal Stroke
Lasso di tempo: From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.

Time from baseline to the first nonfatal stroke, including ischemic and hemorrhagic stroke. Stroke events will be identified through clinical records, hospitalization data, and available neuroimaging findings and confirmed according to standardized diagnostic criteria.

From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
Time to First Serious Arrhythmia
Lasso di tempo: From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.

Time from baseline to the first occurrence of a serious arrhythmia, including sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. Events will be identified through electrocardiograms, ambulatory electrocardiographic monitoring, implanted cardiac device records, hospitalization records, and clinical documentation.

From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Lasso di tempo: Baseline and available follow-up assessments through 10 years.

Change in plasma NT-proBNP concentration from baseline to follow-up, measured using validated clinical laboratory immunoassays and reported in pg/mL. Absolute changes in NT-proBNP concentration will be calculated among participants with available baseline and follow-up measurements. Exploratory analyses will examine the relationship between NT-proBNP levels and cardiovascular outcomes, particularly heart failure events, in participants with available clinical data and biospecimens.

Baseline and available follow-up assessments through 10 years.
Change in Circulating Cardiac Troponin Concentration
Lasso di tempo: Baseline and available follow-up assessments through 10 years.

Change in circulating cardiac troponin concentration from baseline to follow-up, measured using validated clinical laboratory cardiac troponin assays and reported in assay-specific concentration units. Absolute changes will be evaluated among participants with available baseline and follow-up measurements. Exploratory analyses will investigate the relationship between circulating cardiac troponin concentrations and cardiovascular outcomes, particularly myocardial injury and major adverse cardiovascular events.

Baseline and available follow-up assessments through 10 years.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
  • Investigatore principale: Tao Shi, First Affiliated Hospital Xi'an Jiaotong University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

11 novembre 2026

Completamento primario (Stimato)

1 dicembre 2036

Completamento dello studio (Stimato)

1 dicembre 2036

Date di iscrizione allo studio

Primo inviato

8 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi